Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CerusCERS -2.19%78 EV-to-EBIT is 422.02 as of Sep. 10, 2026. GuruFocus rates CERS with a GF Score™ of 78/100 and a GF Value™ of $2.25 (Fairly Valued). The stock has 3 warning signs investors should review. Among 475 Medical Devices & Instruments companies, Cerus ranks worse than 98.32% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cerus's Enterprise Value is $517.0 Mil.
Cerus's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $1.2 Mil. Therefore, Cerus's EV-to-EBIT for today is 422.02.
The historical rank and industry rank for Cerus's EV-to-EBIT or its related term are showing as below:
CERS'
s EV-to-EBIT Range Over the Past 10 Years
Min: -558.94 Med: -15.4 Max: 534.7
Current: 422.02
During the past 13 years, the highest EV-to-EBIT of Cerus was 534.70. The lowest was -558.94. And the median was -15.40.
CERS's EV-to-EBIT is ranked worse than 98.32% of 475
companies
in the Medical Devices & Instruments industry
Industry Median: 18.4
vs CERS: 422.02
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Cerus's Enterprise Value for the quarter that ended in Jun. 2026 was $609.5 Mil.
Cerus's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cerus EV-to-EBIT Related Terms
Cerus EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Cerus's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Cerus's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cerus EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cerus's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Cerus's EV-to-EBIT falls into.
Cerus's current Enterprise Value is $517.0 Mil.
Cerus's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cerus (CERS) has a EV-to-EBIT of 422.02 as of Sep. 10, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cerus and its competitors. According to the industry distribution chart, Cerus ranks #467 out of 475 companies in the Medical Devices & Instruments industry, placing it in the top 98.3%.
Is Cerus' EV-to-EBIT too high?
Cerus' current EV-to-EBIT is 422.02. The Medical Devices & Instruments industry median EV-to-EBIT is 18.40. Cerus' value of 422.02 is 2193.6% above this industry median. Based on the distribution chart, Cerus ranks #467 out of 475 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Cerus has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cerus' EV-to-EBIT compare to TCMD and DCTH?
According to the Medical Devices & Instruments industry distribution chart, Cerus ranks #467 out of 475 companies for EV-to-EBIT. This places Cerus in the lower half of its industry. The industry median EV-to-EBIT is 18.40. Cerus' value of 422.02 is 2193.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.40, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cerus's current EV-to-EBIT of 422.02 is 2193.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cerus and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cerus's current EV-to-EBIT is 422.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cerus stock overvalued right now?
Based on GuruFocus' analysis, Cerus (CERS) is currently considered Fairly Valued. The stock's GF Value™ is $2.25, compared to a current price of $2.46 — trading 9.3% above its estimated fair value. The current EV-to-EBIT is 422.02 and 2193.6% above the Medical Devices & Instruments industry median of 18.40. Cerus' overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Cerus (CERS), the current EV-to-EBIT is 422.02 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cerus (CERS) Overvalued in 2026?
Based on GuruFocus' analysis, Cerus stock appears to be overvalued.
The current stock price of $2.46 is trading 9.3% above its estimated GF Value™ of $2.25.
GuruFocus considers Cerus to be Fairly Valued.
Key valuation signals for CERS:
EV-to-EBIT: 422.02
GF Value™: $2.25 vs. price of $2.46 (9.3% above fair value)
Industry Position: 2193.6% above the Medical Devices & Instruments median (#467 of 475)
No single metric tells the full story. See the CERS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
78GF Score
Get the complete analysis for CERS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CERS has been successfully added to your 
